Glumetinib
产品说明书
 |
同义名 : | Gumarontinib; SCC244 |
| CAS号 : | 1642581-63-2 | |
| 货号 : | A1154012 | |
| 分子式 : | C21H17N9O2S | |
| 纯度 : | 99%+ | |
| 分子量 : | 459.48 | |
| MDL号 : | MFCD31693844 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The receptor tyrosine kinase c-Met plays a critical role in tumor growth, metastasis, tumor angiogenesis, and drug resistance. Glumetinib (SCC244) is an orally bioavailable, small molecule inhibitor of c-Met kinase inhibitor with an IC50 of 0.42 nM. SCC244 is a potent and highly selective inhibitor which displays high selectivity versus 312 other tested protein kinases[1].In xenografts of human tumor cell lines or non-small cell lung cancer and hepatocellular carcinoma patient-derived tumor tissue driven by MET aberration, SCC244 shows antitumor activity and a superior safety margin. What’s more, the in vivo antitumor activity of SCC244 involves the inhibition of c-Met downstream signaling via a mechanism of combined antiproliferation and antiangiogenic effects[1]. Upon oral administration, SCC244 targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. And c-Met inhibitor SCC244 is in clinical trial[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.18mL 0.44mL 0.22mL |
10.88mL 2.18mL 1.09mL |
21.76mL 4.35mL 2.18mL |
| 参考文献 |
|---|